These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8735687)

  • 21. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
    Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
    Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances.
    Gawrońska-Szklarz B; Górnik W; Pawlik A; Kunicki P; Wójcicki J; Sitkiewicz D; Sych Z
    Eur J Clin Pharmacol; 1997; 51(6):431-5. PubMed ID: 9112055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
    Dolzan V; Rudolf Z; Breskvar K
    Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS; Phillips AC; Rieutord A; Shenfield GM
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
    Ashforth EI; Palmer JL; Bye A; Bedding A
    Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.
    Siegmund W; Hanke W; Zschiesche M; Franke G; Biebler KE; Wilke A
    Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):504-9. PubMed ID: 2086491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Debrisoquine hydroxylase and Parkinson's disease.
    Kondo I; Kanazawa I
    Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. pNAT and CYP2D6 gene polymorphism in epileptic patients.
    Borlak JT; Harsany V; Schneble H; Haegele KD
    Biochem Pharmacol; 1994 Nov; 48(9):1717-20. PubMed ID: 7980640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
    Böttiger Y; Dostert P; Benedetti MS; Bani M; Fiorentini F; Casati M; Poggesti I; Alm C; Alvan G; Bertilsson L
    Br J Clin Pharmacol; 1996 Dec; 42(6):707-11. PubMed ID: 8971425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
    Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards].
    González I; Pérez B; Alvarez M; Dorado P; Llerena A
    Med Clin (Barc); 2007 May; 128(20):772-4. PubMed ID: 17568504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.
    Llerena A; Cobaleda J; Martínez C; Benítez J
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):129-38. PubMed ID: 8839686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation.
    Islam SA; Wolf CR; Lennard MS; Sternberg MJ
    Carcinogenesis; 1991 Dec; 12(12):2211-9. PubMed ID: 1747920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.